LOS ANGELES, CA - May 26, 2026 (NEWMEDIAWIRE) - Knee cartilage damage remains one of the most stubborn problems in orthopedic medicine. Unlike many other tissues in the body, articular cartilage has little natural ability to heal because it lacks both direct blood supply and the biological machinery required for meaningful regeneration. For decades, treatment options have reflected that limitation. Microfracture, the long-standing standard of care, attempts to stimulate repair by drilling into the underlying bone in an attempt to mimic a repair trigger. It can provide short-term symptom relief, but long-term cartilage durability remains a recognized challenge with standard treatment. More advanced cell-based therapies exist, but they introduce substantial complexity, cost, manufacturing requirements, and long procedural delays that limit broader adoption. Despite roughly 472,500 arthroscopic knee procedures in the U.S. each year involving knee cartilage damage, the market still lacks an approved, ready-to-use truly regenerative solution capable of combining procedural simplicity with sustained long-term outcomes. Regentis is positioning durability as a central differentiator, with clinical data demonstrating sustained outcomes over extended follow-up periods.

• Approximately 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved off-the-shelf solution capable of regenerating hyaline-like cartilage is currently available in the U.S. market
• Regentis’ GelrinC(R) is a cell-free hydrogel implant designed to repair focal knee cartilage defects in a single approximately 10-minute procedure, with CE Mark approval in Europe and a pivotal U.S. FDA trial now more than 50% enrolled
• A newly patented solvent-free manufacturing process that increases GelrinC(R) production yield by 400% signals Regentis’ preparation for commercial scale-up as clinical and regulatory milestones approach

Regentis Biomaterials (NYSE American: RGNT) is targeting that gap with GelrinC(R), its lead regenerative cartilage repair platform designed as a cell-free alternative to conventional…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.

View the original release on www.newmediawire.com

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Regentis Biomaterials (RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair.